Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Roche Q3 2026 Results: Sales Rise 7%, Xolair Misses
The Roche Q3 2026 results: sales up 7% to CHF 16.13 billion, Ocrevus up 9%, and Xolair below forecasts as a lower-priced rival arrives.
US Ebola Travel Declaration: What Passengers Must Know
The US Ebola travel declaration starts on 3 November 2026: passengers must attest they have not been in the DRC for 21 days. Who it covers and what is unknown.
Shamonda Virus Human Case: What France Confirmed
The Shamonda virus human case in France is the first known infection in a person. Here is what authorities confirmed and what remains unknown.
Natco Generic Risdiplam: Kerala Label Row Explained
The Natco generic risdiplam row in Kerala spans labels, approval status and price: ₹15,900 a bottle versus ₹6.2 lakh for the branded drug.
Mosquirix Malaria Vaccine Price Cut: Key Facts
The Mosquirix malaria vaccine price cut lowers the cost by about 40% to €5.50 a dose, with Bharat Biotech set to take over production.
Moderna Merck Melanoma Vaccine: Phase 3 Data Explained
The Moderna Merck melanoma vaccine plus Keytruda cut recurrence or death risk by 42% in a Phase 3 trial of 1,137 patients. Not yet approved.
Microsoft AI Diagnostic Tool: Study Results Examined
The Microsoft AI diagnostic tool beat general physicians on 300+ hard cases in a Science study. What it measured and what is still unproven.
Medical Device Radiation Protection Study: EggNest Results
A medical device radiation protection study reports lower cath lab doses with EggNest Complete, per Egg Medical. What is and is not known.
Penicillin Manufacturing Europe: Kundl Plant Under Pressure
Penicillin manufacturing Europe still has is concentrated at Sandoz’s Kundl plant, where cheap Chinese imports are raising concern.
Cencora American Oncology Network Acquisition: Full Terms
The Cencora American Oncology Network acquisition is valued at up to $2.4 billion, including up to $100 million in contingent value rights.